Hepion Pharmaceuticals to Participate in the Cantor Oncology, Hematology & HemeOnc Conference


EDISON, N.J., Sept. 26, 2022 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence (“AI”)-driven therapeutic drug development for the treatment of non-alcoholic steatohepatitis (“NASH”), hepatocellular carcinoma (“HCC”), and other chronic liver diseases, today announced that its Chief Medical Officer, Todd Hobbs, MD, will participate in the “Novel Targets in Oncology: Risk vs. Reward” panel at the Cantor Oncology, Hematology & HemeOnc Conference on Wednesday, September 28, 2022 at 9:00 a.m. Eastern Time at the New York Palace Hotel.

See the rest here:
Hepion Pharmaceuticals to Participate in the Cantor Oncology, Hematology & HemeOnc Conference

Related Posts